| Summary: | "Adenovirus vectors (AdV) have attracted considerable interest over the past decade, with ongoing clinical development programs for applications ranging from replacement therapy for protein deficiencies to cancer therapeutics to prophylactic vaccines. In fact, in the period 1989-2005, over 300 clinical trials were conducted using adenoviruses worldwide, adenovirus type 5 (Ad5) being the vector of choice. Consequently, considerable product process, analytical and formulation development has to be carried out in order to respond to the constantly increasing market requirements for AdV.(...)"
|
|---|